Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells

Biochemical Pharmacology

Volumn 46, Issue 10, 1993, Pages 1841-1848

  Meyers, Marian B ^a   Yu, Peter ^b   Mendelsohn, John ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHINESE HAMSTER; CONTROLLED STUDY; LUNG ALVEOLUS CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMAL; CARRIER PROTEINS; CELL DIVISION; CELL LINE; CELL MEMBRANE; CRICETULUS; DACTINOMYCIN; DRUG RESISTANCE; EPIDERMAL GROWTH FACTOR; ETHERS, CYCLIC; HAMSTERS; MEMBRANE GLYCOPROTEINS; OKADAIC ACID; P-GLYCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027381585     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(93)90591-J     Document Type: Article

References (50)

1. Mechanism of multidrug resistance
2. The biochemistry of P-glycoprotein-mediated multidrug resistance
3. Multidrug resistance (vinca alkaloids, actinomycin D, and anthracycline antibiotics)
4. Genetics of multidrug resistance of tumor cells
5. ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells
6. r 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells
7. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance
8. A phosphoglycoprotein associated with taxol resistance in J774.2 cells
9. Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein
10. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine
11. P-Glycoprotein phosphorylation and the multidrug resistance phenotype
12. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells
13. r 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters
14. Mechanisms regulating cell resistance to adriamycin. Evidence that drug accumulation in resistant cells is modulated by phosphorylation of a plasma membrane glycoprotein
15. Phorbol esters induce multidrug resistance in human breast cancer cells
16. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells
17. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells
18. Epidermal growth factor
19. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells
20. Amplification and expression of genes associated with multidrug resistance in mammalian cells
21. Dephosphorylation of P-glycoprotein in DC-3F/AD X cells by epidermal growth factor-activated phosphatase activity
22. Okadaic acid: A new probe for the study of cellular regulation
23. Protein phosphorylation in multidrug resistant Chinese hamster cells
24. Reduced tumor producing capacity of Chinese hamster cells resistant to actinomycin D and daunomycin
25. Altered plasma membrane glycoconjugates of Chinese hamster cells with acquired resistance to actinomycin D, daunorubicin, and vincristine
26. Metabolic and kinetic compartments of the cell cycle distinguished by multiparameter flow cytometry
27. r 170,000 P-glycoproteins in multidrug-resistant human tumor cells
28. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
29. Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cells accompanying development of resistance to daunorubicin and vincristine
30. Protein measurement with the Folin phenol reagent
31. Stimulation of protein phosphatase activity by insulin and growth factors in 3T3 cells
32. Development of a monoclonal antibody against the EGF receptors on mouse cells
33. A and ATP·Mg-dependent protein phosphatase in A431 cells
34. The structure and regulation of protein phosphatases
35. Protein phosphatases come of age
36. Classification of protein serine/threonine phosphatases: Identification and quantitation in cell extracts
37. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells
38. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics
39. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements
40. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists
41. Protein kinase C inhibition of the epidermal growth factor receptor tyrosine kinase activity is independent of the oligomeric state of the receptor
42. Epidermal growth factor receptor synthesis is stimulate by phorbol ester and epidermal growth factor
43. Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein
44. The human multidrug resistance 1 promoter has an element that responds to serum starvation
45. Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity
46. Induction of c-fos gene and protein by growth factors precedes activation of c-myc
47. Protein phosphatase 2A potentiates activity of promoters containing AP-1 binding elements
48. Adriamycin causes upregulation of epidermal growth factor receptors in actively growing cells
49. Modulation of epidermal growth factor receptor (EGFR)/Transforming growth factor-α (TGFα) pathway by adriamycin (ADR)
50. Epidermal growth factor reduces resistance to doxorubicin